Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00006028
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00006027
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Community Hospital of Los Gatos, Los Gatos, California, United States
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Target Recruit Count
- 300
- Registration Number
- NCT00039039
- Locations
- 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇮🇹Ospedale Mariano Santo, Cosenza, Italy
🇮🇹Ospedale San Martino, Genoa, Italy
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT00046917
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 30
- Registration Number
- NCT00031590
- Locations
- 🇺🇸
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 70
- Registration Number
- NCT00011999
- Locations
- 🇺🇸
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 750
- Registration Number
- NCT00003053
- Locations
- 🇮🇹
Ospedale San Filippo Neri, Rome, Italy
🇮🇹Universita Degli Studi di Bari Policlinico, Bari, Italy
🇮🇹Ospedale Oncologico A. Businco, Cagliari, Italy
Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 105
- Registration Number
- NCT00005087
- Locations
- 🇺🇸
Mount Diablo Medical Center, Concord, California, United States
🇺🇸Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States
🇺🇸Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00005830
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 46
- Registration Number
- NCT00004141
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.